PhosphoGam
PhosphoGam
Non-viral allogeneic CAR-T cell therapy for cancer
PhosphoGam makes CAR-T more potent, safer, and higher scale,
With a 90% reduction in manufacturing cost vs conventional CAR-T, and the scale to treat large patient populations, based on:
​
-
Revolutionary gamma/delta-t cell (γδ-T cell) manufacturing with exceptional cell fitness, limitless scale, high consistency and game-changing economics.
​
-
Non-viral allogeneic CAR-T technology, with unbeatable cell construction quality, safety, speed, and economics.
​
-
Unique application strategies: re-dosing, tumor-homing, and zero therapeutic persistence for better patient outcomes.
​​
​
γδ-T cell manufacturing
​
Limitless scale, unbeatable cell fitness, revolutionary economics.
​
Until now, it has been impossible to expand (“manufacture”) γδ-t cells in sufficient quantity, quality and consistency. Conventional γδ-T cell manufacturing technologies are highly variable and prone to overstimulation leading to exhaustion or cell death.
PhosphoGam’s γδ-T cell manufacturing platform is based on proprietary small molecule expansion agents which enable exquisite control of the expansion process and can produce near-limitless quantities of γδ-T cells from healthy donors. PhosphoGam focuses on cell fitness, which is essential for high cell potency and consistent manufacturing.
PhosphoGam can consistently produce highly pure, highly active γδ-t cells at a scale capable of addressing major cancer markets, of >20,000 patients/year. Combining yield & economy, the PhosphoGam platform is 80,000x more efficient than conventional γδ-t cell expansion.
Non-viral allogeneic CAR-T
​
High quality cell manufacturing enables high quality CAR-T.
PhosphoGam builds highly potent CAR-T cells with >95% cell viability, transfection efficiency, and CAR expression, with very low batch-to-batch variability. The key is the fitness of the expanded cells, modified with gentle mRNA electroporation, not viral transduction.
PhosphoGam has developed an mRNA CAR- γδ-T cell platform with notable advantages:
-
Optimal CAR-T cell construction, with unbeatable high & consistent CAR-T cell qualities and recoverability, which increases potency and reduces the manufacturing burden
-
Allogeneic application, without edits, No complex edits required and no “Allo tax” on manufacturing.
-
Safety – Non-viral construction and PhosphoGam’s unique ex vivo durability strategy eliminates risk of secondary cancers, with a lower risk of CRS/neurotoxicity due to transient mRNA expression and intentional lack of cell persistence;
-
Ease of engineering & rapid R&D cycle time. New mRNA product development is much quicker than viral product development.
-
Manufacturing scale to treat 10,000’s per year from one GMP suite.
-
Unbeatable economics: 90% lower manufacturing cost vs conventional CAR-T.
​
​​
Application
​
Novel strategies to enhance efficacy and increase safety.
The world’s best gamma/delta-T cell manufacturing platform and extremely powerful CAR-T are amplified by innovative therapeutic strategies to deliver more cells to the tumor, quicker, and repeatedly.
​
Re-dosing. Zero persistence required. With abundant, consistent, and economical manufacturing, PhosphoGam is uniquely capable of solving therapeutic durability through ex vivo manufacturing and economical redosing. Fresh, fit cells re-dosed from different healthy donors solves therapeutic durability without edits, enhances efficacy and decreases toxicity.
Tumor-homing. CAR-T built on γδ-T cells have natural homing capabilities, especially when used against tumor cells that have been "sensitized" to γδ-T cells by conventional chemotherapy. PhosphoGam has developed technology to enhance trafficking of CAR-T cells to the tumor, increasing efficacy by delivering more killer cells on-target, faster.
​
​
Gamma/delta-T cells (γδ-T cells)
​
Allogeneic, able to penetrate solid tumors, and more potent than conventional T-cells
PhosphoGam leverages the unique biology of γδ-T cells to create extremely potent T-cell therapies that can preferentially traffic to tumors.
γδ--T cells are the first responders of the immune system and act as part of both the adaptive and innate immune response. Unlike conventional T-cells. these rare cells are broadly capable of recognizing and killing malignancies, serial killing, and recruiting other immune cells to mount a response to cancer.
γδ--T cells are ideal for allogeneic (“off-the-shelf”) application and are capable of penetrating solid tumors.
​
About Us
PhosphoGam, located in Durham, NC, is based on the research of Dr. Richard Lopez, a Duke University physician/scientist. Dr. Lopez is an associate professor of hematologic malignancies & cell therapy at Duke and is a thought leader in γδ-T cell immunobiology.
​
PhoshoGam has been seeded by a leading biotech VC and has worked with pharmaceutical/biotech companies across three continents.
​​
​
To connect with PhosphoGam, email Tim Gallagher, PhosphoGam Chief Business Officer: Tim (at) PhosphoGam.com
